1. 9 If applicable, prevalence in the ethnic group of investigated person Not applicable.
Diagnostic setting
Comment D: Meaningful but not yet approved.
TEST CHARACTERISTICS
2.1 Analytical sensitivity (proportion of positive tests if the genotype is present) 100%.
Analytical specificity (proportion of negative tests if the genotype is not present) 100%.
2.3 Clinical sensitivity (proportion of positive tests if the genotype is present) 20, 21 470%. 20, 21 The clinical specificity can be dependent on variable factors, such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case. 495%.
Clinical specificity (proportion of negative tests if the disease is not present)

2.5
Positive clinical predictive value (life time risk to develop the disease if the test is positive) 20, 21 Life-time risk to develop the disease when patient is exposed to 'trigger' anesthetics is 475%.
2.6
Negative clinical predictive value (probability not to develop the disease if the test is negative) 20, 21 Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: B90%.
Index case in that family had not been tested: B15%. 3.4 Prenatal diagnosis 3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnostic? Prenatal diagnosis is not yet approved solely for MH diagnosis but would be a promising option and would make sense if the familial MH mutation is known. PND could increase patient safety, for example, for the newborn of MH positive parents (MH-positive mother or father, newborn is 50% at risk) under the situation of a Cesarean section. In this case MH triggering agents (given under general anesthesia) must be avoided even if the mother is negative.
On the other hand, prenatal diagnosis is an important option for other congenital RYR1-related disorders and if such an indication is given the search for MH-associated mutations could be taken under consideration. Triggering agents of malignant hyperthermia (volatile anaesthetics, depolarizing muscle relaxant succinylcholine) must be avoided during general anaesthesia; special preparation of the anaesthesia machine is required before general anaesthesia, relatives of those diagnosed are advised to be tested and followed precautions as above.
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Yes. If a mutation associated with CCD or MmD is found, the patient should be followed for evidence of muscle weakness. Prenatal counseling is advised in such cases.
Family members should be treated as MH susceptible until IVCT/ CHCT test is done with a negative result.
